A comparison of open surgery versus endovascular repair of unstable ruptured abdominal aortic aneurysms  by Gupta, Prateek K. et al.
From the Society for Vascular SurgeryA comparison of open surgery versus endovascularFrom
C
Sa
H
Auth
The
Im
A
an
co
vi
Pres
Su
Rep
of
W
The
to
m
0741
Pub
httprepair of unstable ruptured abdominal aortic
aneurysms
Prateek K. Gupta, MD,a Bala Ramanan, MBBS,b Travis L. Engelbert, MD,c Girma Tefera, MD,c
John R. Hoch, MD,c and K. Craig Kent, MD,c Memphis, Tenn; San Francisco, Calif; and Madison, Wisc
Objective: Two randomized trials to date have compared open surgery (OS) and endovascular (EVAR) repair for ruptured
abdominal aortic aneurysm (rAAA); however, neither addressed optimal management of unstable patients. Single-center
reports have produced conﬂicting data regarding the superiority of one vs the other, with the lack of statistical power due
to low patient numbers. Furthermore, previous studies have not delineated between the outcomes of stable patients with a
contained rupture vs those patients with instability. Our objective was to compare 30-day outcomes in patients under-
going OS vs EVAR for all rAAAs, focusing speciﬁcally on patients with instability.
Methods: Patients who underwent repair of rAAA were identiﬁed from the American College of Surgeons (ACS) National
Surgical Quality Improvement Program (NSQIP) database (2005 to 2010). Unstable patients with rupture were identiﬁed
as those who were American Society of Anesthesiologists Physical Status Classiﬁcation 4 or 5 requiring emergency repair
with at least one of the following: preoperative shock, preoperative transfusion of >4 units, preoperative intubation, or
preoperative coma or impaired sensorium. Univariable and multivariable logistic regression analyses were performed.
Results: Of the 1447 patients with rAAA, 65.5% underwent OS and 34.5% EVAR. Forty-ﬁve percent were unstable, and
for these patients, OS was performed in 71.3% and EVAR in 28.7%. The 30-day mortality rate was 47.9% (OS, 52.8%;
EVAR, 35.6%; P < .0001) for unstable rAAAs and was 22.4% for stable rAAAs (OS, 26.3%; EVAR, 16.4%; P [ .001).
Amongst patients with unstable rAAA, 26% had a myocardial infarction or cardiac arrest #30 days (OS, 29.0%; EVAR,
19.1%; P [ .006), and 17% needed postoperative dialysis (OS, 18.7%; EVAR, 12.8%; P [ .04). Amongst patients with
stable rAAA, 13.6% had a myocardial infarction or cardiac arrest #30 days (OS, 14.9%; EVAR, 11.6%; P [ .20), and
11.5% needed postoperative dialysis (OS, 13.3%; EVAR, 8.7%; P [ .047). Multivariable analyses showed OS was a
predictor of 30-day mortality for unstable rAAA (odds ratio, 1.74; 95% conﬁdence interval, 1.16-2.62) and stable rAAA
(odds ratio, 1.64; 95% conﬁdence interval, 1.10-2.43).
Conclusions: Approximately one-third of patients treated for rAAA undergo EVAR in NSQIP participating hospitals. Not
surprisingly, unstable patients have less favorable outcomes. In both stable and unstable rAAA patients, EVAR is asso-
ciated with a diminished 30-day mortality and morbidity. (J Vasc Surg 2014;60:1439-45.)Despite advances in trauma andcritical caremanagement,
emergency systems, and operative techniques, treatment of
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://dx.doi.org/10.1016/j.jvs.2014.06.122aneurysm repair (EVAR) for this condition has recently
gained acceptance.1,2 For elective AAA repair, there are
multiple randomized trials including Dutch Randomised
Endovascular Aneurysm Management (DREAM),3 Endo-
vascular vs Open Abdominal Aortic Aneurysm Repair
(EVAR I),4 and Veterans Affairs Open vs Endovascular
Repair (OVER),5 that have compared open surgery
(OS) with EVAR.
However, the Amsterdam Acute Aneurysm trial6 has
been the only randomized controlled trial (RCT) to date
comparing OS vs EVAR for rAAA. Interestingly, the
Amsterdam investigators did not ﬁnd a perioperative sur-
vival beneﬁt for EVAR. This trial, however, was isolated
to patients with rAAA that were hemodynamically stable.
Of signiﬁcance, the trial excluded 78% of patients present-
ing with rAAA, many because of hemodynamic instability.
Earlier this year, the Immediate Management of the
Patient with Rupture: Open vs Endovascular Repair
(IMPROVE) trial7 was published comparing EVAR vs
OS for rAAA. Although this trial included unstable pa-
tients, the outcome of endovascular and open approaches
were not compared in this cohort. Thus, no study in the
current literature addresses the optimal management of un-
stable rAAAs. Our objectives with this evaluation were to1439
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Surgical Quality Improvement Program (NSQIP) database
to compare 30-day outcomes in patients undergoing OS
vs EVAR for all rAAAs and speciﬁcally for the subset of
patients with unstable rAAAs.
METHODS
Data set. Data were extracted from the 2005 to 2010
NSQIP Participant Use Data Files. These are multicenter,
prospective databases with 121 (years 2005 to 2006),
183 (year 2007), 211 (year 2008), 237 (year 2009), and
258 (year 2010) participating academic and community
United States hospitals. Data are collected inclusive of
>250 perioperative variables. In NSQIP, a participant hos-
pital’s surgical clinical reviewer (SCR) uses a variety of
methods to capture, one of which is medical record
abstraction. The data are collected based on strict criteria
formulated by a committee. To ensure the data collected
are of high quality, the NSQIP has developed training
mechanisms for the SCR, and inter-rater reliability audit
of participating sites is conducted. Inter-rater reliability
audits revealed that in 2008, total disagreements were only
1.60% (>140,000 audited ﬁelds).8 NSQIP hospitals are
required to provide complete 30-day follow-up on at least
95% of patients.9 The processes of SCR training, inter-rater
reliability auditing, data collection, and sampling method-
ology have been previously described in detail.
Patients. Patients treated for rAAA were identiﬁed
from the ACS NSQIP database (2005 to 2010) using
the Current Procedural Terminology (CPT) code (Amer-
ican Medical Association, Chicago, Ill) of the procedures
combined with International Classiﬁcation of Diseases,
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diag-
nosis code for rAAA (441.3). EVAR was deﬁned with any
of the CPT codes 34800, 34802, 34803, 34804, 34805,
or 34825. OS repair was deﬁned with CPT codes 35801
or 35102. Preoperative data included demographic, life-
style, comorbidity, and other variables.10 Because patient
information was acquired from the publicly available
NSQIP data set, with patients not being individually
identiﬁed, Institutional Review Board approval was
waived.
Deﬁnition of hemodynamic instability. There is not
a speciﬁc code available that connotes hemodynamic insta-
bility; thus, we created a surrogate using a series of quali-
fying codes. A patient with a rAAA was considered
“unstable” if all of the following three criteria were met:
1) The operation was an emergency;
2) The patient had an American Society of Anesthesiol-
ogists (ASA) Physical Status Classiﬁcation of 4 (a
patient with severe systemic disease that is a constant
threat to life) or 5 (a moribund patient who is not
expected to survive without the operation); and
3) One or more of (1) preoperative shock/systemic
inﬂammatory response syndrome or (2) preoperative
packed red blood cell transfusion >4 units or (3) pre-
operative intubation, or (4) preoperative impairedsensorium (deﬁned in NSQIP as acute confusion/
delirium/mental status changes #48 hours of surgi-
cal procedure).
Outcome. The primary outcome of interest was
30-day mortality. Secondary outcomes included 30-day
cardiac arrest or myocardial infarction (MI), acute renal
failure, and failure to wean from the ventilator #48 hours,
as well as a number of other postoperative complications,
which are reported in Table I. The NSQIP database cap-
tures outcomes for 30 postoperative days.
Statistical analysis. Univariable analysis was per-
formed using the Pearson c2 test or the Fisher exact test
for categoric variables and the t-test or F test for contin-
uous variables. Forward stepwise multiple logistic regres-
sion analyses were performed to assess factors associated
with the primary and all of the secondary study outcomes.
The inclusion criterion for multivariable analysis was P < .1
on univariable analysis. Statistical analyses were performed
using SPSS 17.0 software (SPSS Inc, Chicago, Ill). A P
value of < .05 was considered signiﬁcant.
RESULTS
From 2005 to 2010, 1447 patients underwent an oper-
ation for rAAA; of these, 793 patients (54.8%) were stable,
and the rest (45.2%) were classiﬁed as unstable. The 30-day
mortality rate for the overall cohort was 33.9% (OS, 39.3%;
EVAR, 23.6%; P < .0001). Preoperative demographics and
comorbidities are listed in Table II, and postoperative out-
comes are included in Table I.
Patients with stable rAAAs. Amongst the 793 stable
ruptures, 482 (60.8%) underwent OS and 311 (39.2%) un-
derwent EVAR. The data in Table II show that in the
stable rAAA cohort, patients with a higher ASA class ten-
ded to be selected for OS rather than EVAR (P ¼ .02).
There were more patients with diabetes (15% vs 10%; P ¼
.02), chronic obstructive pulmonary disease (20.3% vs
14.9%; P ¼ .03), and on dialysis (2.6% vs 0.6%; P ¼ .03) in
the EVAR subgroup than in the OS subgroup.
The 30-day mortality was signiﬁcantly greater for OS vs
EVAR (26.3% vs 16.4%; P ¼ .001). The 30-day rate of
acute renal failure requiring dialysis was 13.3% for OS vs
8.7% for EVAR (P ¼ .047). The rate of cardiac arrest or
MI was 14.9% for OS vs 11.6% for EVAR (P ¼ .20).
Although there was no difference in rate of cardiac arrest
or MI, OS patients had a higher rate of cardiac arrest alone
compared with EVAR (10.2% vs 5.5%; P ¼ .02). The rate
of ventilator dependence >48 hours was 44.6% for OS and
15.4% for EVAR (P < .0001). The two groups had a
similar rate of return to the operating room (23% vs 21%;
P ¼ .42). The mean hospital length of stay was signiﬁcantly
shorter for EVAR vs OS (8.7 vs 13.8 days; P < .0001).
Compared with EVAR patients, patients who underwent
OS had a higher rate of urinary tract infection (5.6% vs
1.9%; P ¼ .01), pneumonia (20.1% vs 8.4%; P < .0001),
reintubation (11.8% vs 6.4%; P ¼ .01), deep venous throm-
bosis (4.8% vs 1.9%; P ¼ .04), and coma (1.9% vs 0; P ¼
.01). Table I reports for details on univariable analysis of
Table I. Postoperative Events with Univariable Analysis
Thirty-day outcomesa
Stable rAAA Unstable rAAA
OS (n ¼ 482) EVAR (n ¼ 311) P valueb OS (n ¼ 466) EVAR (n ¼ 188) P valueb
Wound infection
Superﬁcial 8 (1.7) 9 (2.9) .32 8 (1.7) 10 (5.3) .02
Deep 3 (0.6) 2 (0.6) .99 3 (0.6) 3 (1.6) .4
Wound dehiscence 10 (2.1) 3 (1.0) .27 12 (2.6) 3 (1.6) .57
Urinary tract infection 27 (5.6) 6 (1.9) .01 34 (7.3) 15 (8.0) .75
Transfusion >4 units PRBC post-op 111 (23.0) 61 (19.6) .26 138 (29.6) 58 (30.9) .76
Pneumonia 97 (20.1) 26 (8.4) <.0001 111 (23.8) 37 (19.7) .25
Reintubation 57 (11.8) 20 (6.4) .01 41 (8.8) 24 (12.8) .13
Failure to extubate at 48 hours 215 (44.6) 48 (15.4) <.0001 210 (45.1) 68 (36.2) .04
Deep venous thrombosis 23 (4.8) 6 (1.9) .04 18 (3.9) 9 (4.8) .66
Pulmonary embolism 10 (2.1) 4 (1.3) .58 5 (1.1) 4 (2.1) .29
Renal insufﬁciency 22 (4.6) 7 (2.3) .09 25 (5.4) 6 (3.2) .31
Acute renal failure requiring dialysis 64 (13.3) 27 (8.7) .047 87 (18.7) 24 (12.8) .07
Stroke 8 (1.7) 4 (1.3) .77 13 (2.8) 2 (1.1) .18
Coma 9 (1.9) 0 .01 6 (1.3) 0 .19
Cardiac arrest 49 (10.2) 17 (5.5) .02 114 (24.5) 26 (13.8) .003
MI 26 (5.4) 21 (6.8) .43 24 (5.2) 12 (6.4) .53
Return to operating room 111 (23.0) 64 (20.6) .42 98 (21.0) 45 (23.9) .42
Hospital length of stay, days 13.8 6 16.3 8.7 6 13.8 <.0001 12.7 6 16.9 12.4 6 14.8 .87
Death 127 (26.3) 51 (16.4) .001 246 (52.8) 67 (35.6) <.0001
EVAR, Endovascular aortic repair; MI, myocardial infarction; OS, open surgery; PRBC, packed red blood cells; rAAA, ruptured abdominal aortic aneurysm.
aCategoric data are shown as number (%) and continuous data as mean 6 standard deviation.
bThe P value reﬂects univariate analysis: Pearson c2 test and analysis of variance F test comparing the preoperative variables between OS and EVAR. P < .05 is
signiﬁcant.
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signiﬁcant, outcomes favored EVAR.
Multivariable analyses showed OS was associated with
higher risk than EVAR of 30-day mortality (odds ratio
[OR], 1.64; 95% conﬁdence interval [CI], 1.10-2.43)
and failure to wean from the ventilator within 48 hours
(OR, 4.08; 95% CI, 2.80-5.95). Although a trend was
evident, multivariable analyses did not reveal a signiﬁcant
association of OS vs EVAR with 30-day acute renal failure
requiring dialysis (P ¼ .09). There was not an association of
OS vs EVAR with 30-day cardiac arrest or MI (P ¼ .58).
Unstable rAAAs. Amongst 654 patients with rAAAs
that were unstable, 466 (71.3%) underwent OS and 188
(28.7%) were treated with EVAR. As reported in
Table II, patients in the unstable rAAA cohort with a
higher ASA class also tended to be selected for OS rather
than EVAR (P < .0001). There were more patients with
peripheral arterial disease with history of revascularization
or amputation (7.4% vs 2.6%; P ¼ .004) and history of
stroke with neurologic deﬁcit (6.9% vs 3.2%; P ¼ .05) in
the EVAR subgroup than in the OS subgroup. There were
more patients with hypertension (67.6% vs 58.5%; P ¼ .03)
and impaired sensorium (23.8% vs 16.0%; P ¼ .03) in the
OS subgroup than in the EVAR subgroup.
The 30-day mortality was signiﬁcantly higher for OS
(52.8%) vs EVAR (35.6%; P < .0001). The 30-day rate
of acute renal failure requiring dialysis was 18.7% for OS
in contrast to 12.8% for EVAR (P ¼ .07). The rate of car-
diac arrest or MI was 29.0% for OS vs 19.1% for EVAR
(P ¼ .006). This ﬁnding was strongly inﬂuenced by a
higher rate of cardiac arrest (24.5% vs 13.8%; P ¼ .003).A signiﬁcant difference was not found in the rate of MI
(5.2% vs 6.4%; P ¼ .53). Forty-ﬁve percent of patients un-
dergoing OS remained on the ventilator 48 hours after the
operation in contrast to 36% of EVAR patients (P ¼ .04).
The two interventions had similar rates of return to the
operating room (21% vs 24%; P ¼ .42) and mean hospital
length of stay (12.7 vs 12.4 days; P ¼ .87). OS had a lower
rate of superﬁcial wound infection (1.7% vs 5.3%; P ¼ .02).
Details on univariable analysis of other postoperative out-
comes are reported in Table I. For all variables that were
signiﬁcant, outcomes favored EVAR.
Multivariable analyses showed OS was associated with
higher risk for 30-day mortality than EVAR (OR, 1.74;
95% CI, 1.16-2.62), 30-day acute renal failure requiring
dialysis (OR, 1.81; 95% CI, 1.04-3.13), failure to wean
from the ventilator #48 hours (OR, 1.55; 95% CI, 1.08-
2.23), and 30-day cardiac arrest or MI (OR, 1.75; 95%
CI, 1.09-2.82).
Effect of year of operation on outcomes. From 2005
to 2010, the percentage of patients with rAAA who under-
went an EVAR increased (Table II) in both the stable (P <
.0001) and unstable rAAA cohorts (P ¼ .006). There was
no difference in major morbidity or mortality (P > .05)
during those years, except for a decline in the rates of
postoperative pneumonia in the stable (P < .0001) and
unstable (P ¼ .004) cohorts.
DISCUSSION
Although EVAR has an established role in the elective
treatment of aneurysms, the evidence to support its use as
the primary treatment for patients with rAAAs remains
Table II. Patient characteristics with univariable analysis
Characteristicsa
Stable rAAA Unstable rAAA
OS (n ¼ 482) EVAR (n ¼ 311) P valueb OS (n ¼ 466) EVAR (n ¼ 188) P valueb
Preoperative
Cardiac
Prior cardiac surgery 87 (18.0) 45 (14.5) .19 68 (14.6) 31 (16.5) .54
Congestive heart failure 12 (2.5) 5 (1.6) .46 6 (1.3) 2 (1.1) 1.0
MI #6 months 3 (0.6) 7 (2.3) .06 16 (3.4) 10 (5.3) .26
Prior PCI 49 (10.2) 40 (12.9) .24 44 (9.4) 16 (8.5) .71
Circulatory
Bleeding disorder 73 (15.1) 56 (18.0) .29 83 (17.8) 35 (18.6) .81
PADc 21 (4.4) 15 (4.8) .76 12 (2.6) 14 (7.4) .004
Transfusion >4 units pre-op 7 (1.5) 3 (1.0) .75 79 (17.0) 38 (20.2) .33
General
Age, median years 74 73 .98 74 73 .86
ASA class
2 6 (1.2) 5 (1.6) .02 e e
3 83 (17.2) 81 (26.0) e e
4 284 (58.9) 174 (55.9) 230 (49.4) 123 (65.4) <.0001
5 105 (21.8) 50 (16.1) 236 (50.6) 65 (34.6)
BMI, median kg/m2 28.3 26.8 .09 29.2 29.4 .84
Diabetes mellitus 46 (9.5) 46 (14.8) .02 51 (10.9) 21 (11.2) .93
Dependent functional status 43 (8.9) 35 (11.3) .55 108 (23.3) 35 (18.6) .19
Hypertension 320 (66.4) 214 (68.8) .48 315 (67.6) 110 (58.5) .03
Race .40 .98
American Indian 0 2 (0.6) 2 (0.4) 1 (0.5)
Asian/Paciﬁc Islander 6 (1.2) 1 (0.3) 5 (1.1) 2 (1.1)
Hispanic 9 (1.9) 6 (1.9) 10 (2.1) 4 (2.1)
Black 26 (5.4) 18 (5.8) 18 (3.9) 10 (5.3)
Unknown 63 (13.1) 38 (12.2) 61 (13.1) 24 (12.8)
White 378 (78.4) 246 (79.1) 370 (79.4) 147 (78.2)
Sex .49 .50
Male 370 (76.8) 243 (78.1) 353 (75.9) 138 (73.4)
Female 110 (22.8) 68 (21.9) 112 (24.1) 50 (26.6)
SIRS/shock, pre-op .42 .59
SIRS 27 (5.6) 13 (4.2) 247 (53.1) 105 (56.1)
Shock (SIRS þ organ dysfunction) 8 (1.7) 8 (2.6) 74 (15.9) 24 (12.8)
Year <.0001 .006
2005 22 (4.6) 3 (1.0) 17 (3.6) 3 (1.6)
2006 43 (8.9) 20 (6.4) 57 (12.2) 12 (6.4)
2007 97 (20.1) 39 (12.5) 95 (20.4) 24 (12.8)
2008 122 (25.3) 78 (25.1) 102 (21.9) 46 (24.5)
2009 106 (22.0) 79 (25.4) 88 (18.9) 43 (22.9)
2010 92 (19.1) 92 (29.6) 107 (23.0) 60 (31.9)
Laboratory
Mean creatinine, mg/dL 1.2 1.2 .23 1.5 1.5 .63
Mean hematocrit, % 35.9 35.5 .79 33.1 33.2 .99
Neurologic
Coma 2 (0.4) 0 (0) .5 46 (9.9) 13 (6.9) .23
Impaired sensorium 4 (0.8) 2 (0.6) 1.0 111 (23.8) 30 (16.0) .03
Stroke with neurologic deﬁcit 11 (2.3) 12 (3.9) .20 15 (3.2) 13 (6.9) .05
Stroke without neurologic deﬁcit 24 (5.0) 23 (7.4) .16 22 (4.7) 9 (4.8) 1.0
Transient ischemic attack 19 (3.9) 13 (4.2) .86 17 (3.6) 9 (4.8) .51
Renal
Dialysis, pre-op 3 (0.6) 8 (2.6) .03 4 (0.9) 3 (1.6) .42
Mean GFR, mL/min/1.73 m2 59.3 59.8 .41 56.4 55.9 .84
Respiratory
Chronic obstructive pulmonary disease 72 (14.9) 63 (20.3) .03 91 (19.5) 29 (15.4) .22
Dyspnea .08 .26
At rest 34 (7.1) 17 (5.5) 92 (19.7) 29 (15.4)
On moderate exertion 36 (7.5) 37 (11.9) 36 (7.7) 11 (5.9)
On ventilator, pre-op 11 (2.3) 2 (0.6) .06 170 (36.5) 56 (29.8) .10
Social
Alcohol intake within the last 2 weeks 28 (5.8) 20 (6.4) .72 22 (4.7) 6 (3.2) .38
Smoking within the past year 182 (37.8) 119 (38.3) .47 153 (32.8) 60 (31.9) .82
(Continued on next page)
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Table II. Continued.
Characteristicsa
Stable rAAA Unstable rAAA
OS (n ¼ 482) EVAR (n ¼ 311) P valueb OS (n ¼ 466) EVAR (n ¼ 188) P valueb
Intraoperative
Therapy
Regional anesthesia 0 29 (9.3) <.0001 0 10 (5.3) <.0001
Percutaneous approach 0 154 (49.5) <.0001 89 (47.3) <.0001
Intra-op RBC transfusion, mean units 9.1 3.2 <.0001 12 8 <.0001
Median operative time, minutes 198 149 <.0001 191 179 .13
Surgeon .17 .30
Vascular 462 (60.3) 304 (39.7) 448 (71.7) 177 (28.3)
General 20 (74.1) 7 (25.9) 18 (62.1) 11 (37.9)
ASA, American Society of Anesthesiologists Physical Status Classiﬁcation; BMI, body mass index; EVAR, endovascular aortic repair;MI, myocardial infarction;
PAD, peripheral arterial disease; rAAA, ruptured abdominal aortic aneurysm; OS, open surgery; PAD, peripheral arterial disease; RBC, red blood cell; SIRS,
systemic inﬂammatory response syndrome.
aCategoric data are shown as number (%) and continuous data as indicated.
bP value reﬂects univariate analysis: Pearson c2 test and analysis of variance F test, comparing the preoperative variables between OS and EVAR. P < .05 is
signiﬁcant.
cWith a history of revascularization or amputation.
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rise in the proportion of patients with rAAA treated with
EVAR, from 6.6% in 2001 to 42.1% in 2010.11 Most
studies on the use of EVAR for rAAA are derived from
single-center case series or population-based evalua-
tions.12 The Nottingham Pilot Trial conducted by Hin-
chliffe et al13 was the ﬁrst, single-center prospective
RCT of EVAR compared with OS for rAAA. The trial
was stopped because it was underpowered and slow to re-
cruit; thus, no conclusions were made regarding mortal-
ity, but the authors did conclude that preoperative
computed tomography scanning does not delay treatment
of rAAAs.
The Amsterdam Acute Aneurysm Trial6 was the ﬁrst
completed multicenter RCT comparing OS vs EVAR for
rAAA; however, severe hemodynamic instability was an
exclusion criterion for that study, and 78% of identiﬁed
patients were not recruited into the trial. The results
from the United Kingdom-based IMPROVE trial were
published earlier this year.7 This trial included unstable
patients (48% of the total) but did not address the ques-
tion of optimum management of this speciﬁc cohort.
Thus, the primary goal of our analysis was to further
evaluate the value of EVAR in the treatment of rAAA
by using a relatively robust nationwide data set. More-
over, we aimed to compare the outcomes of EVAR
and OS in the treatment of ruptured aneurysms in stable
vs unstable patients.
We found that patients undergoing EVAR had a
signiﬁcantly improved 30-day mortality compared with
OS for both cohorts, patients with rAAAs that were stable
as well as those that were not. Data from several United
States population-based studies have revealed a mortality
rate for ruptured AAA that ranges from 31% to 58% after
EVAR and from 38% to 56% after OS.2,14-17 Veith et al18
collected data from 49 centers around the world using
EVAR for rAAA and found a 30-day mortality of 21.2%
after EVAR in 1037 patients vs 36.3% for 763 patientsin a comparative OS group (P < .0001). That study did
not classify patients as stable vs unstable. The authors
concluded that at high-volume centers, high-risk patients
beneﬁt from EVAR.
The Amsterdam Acute Aneurysm Trial revealed a 30-
day mortality of 21% for EVAR vs 25% for OS in 116 he-
modynamically stable patients that met the inclusion
criteria. Thus, these investigators were not able to
demonstrate an advantage of EVAR in a stable rupture
population. In the IMPROVE trial, 275 rAAA patients
randomized to an endovascular strategy had a 30-day
mortality of 36.4% vs 40.6% in the 261 open repair pa-
tients (P ¼ .3). However, of the 275 patients with
rAAA in the endovascular strategy group, EVAR was
attempted in only 154 (56%) due to anatomic unsuitabil-
ity, crossover, and other reasons. Overall 30-day mortality
in patients who underwent an EVAR in the IMPROVE
trial was 25% compared with 38% for those who under-
went OS.
Our data also demonstrate an advantage of EVAR
with regard to overall morbidity in stable and unstable
patients, except for wound infections. In terms of post-
operative renal failure requiring dialysis, EVAR was su-
perior to OS for unstable patients, with a similar trend
for patients with stable rupture. A decreased incidence
of moderate to severe renal failure was associated with
EVAR in the Amsterdam Acute Aneurysm Trial. There
are several possible explanations for the increased inci-
dence of renal failure after OS, including greater ﬂuid
and electrolyte shifts after laparotomy, the need for a
prolonged suprarenal clamp, hypotension after laparot-
omy, and decompression of the abdomen or retroperito-
neum. Our data showed EVAR in the unstable cohort
was also associated with lower rate of 30-day postoper-
ative cardiac arrest or MI, and no differences were
observed in cardiac outcomes observed in the stable
patient cohort. These ﬁndings are identical to those
of the Amsterdam Acute Aneurysm Trial, where severe
JOURNAL OF VASCULAR SURGERY
1444 Gupta et al December 2014postoperative cardiac complications were similar be-
tween the two procedures.
Our study also demonstrates the superiority of EVAR
with regard to postoperative respiratory failure in the stable
and unstable cohorts. These ﬁndings are supported by
Nedeau et al,19 who also showed less postoperative respira-
tory failure in patients treated by EVAR for rAAA. Patients
treated by EVAR had a higher rate of wound infection than
patients treated with OS. This is probably because groin in-
cisions are known to have higher risk of wound infections
than abdominal incisions for cases without enteral contam-
ination. The risk of wound infection is also higher in emer-
gency settings than in elective procedures, as shown by the
higher rates of wound infections among unstable rAAA pa-
tients who underwent EVAR compared with stable rAAA
patients.
Despite our favorable ﬁndings, there are genuine con-
cerns and impediments to the adoption of an EVAR-ﬁrst
approach for all rAAAs. There are disparities in institu-
tional experience with EVAR, and outcomes of EVAR
have been shown to be dependent on the institutional
volume.2 To this end, urgent EVAR for rAAAs in unsta-
ble patients requires (1) a broad selection of grafts readily
available, (2) the availability of a call team inclusive of in-
dividuals experienced in catheter-based intervention, and
(3) appropriate intraoperative imaging. The lack of expe-
rience or preparedness is greatly exacerbated when
attempting to urgently treat an unstable patient.12 More-
over, although advances in endograft technology have
allowed up to 80% of patients to be anatomically suitable
for EVAR, a cohort of patients remains for whom EVAR
is not possible.11 Despite these limitations, our study,
which includes data from a wide variety of institutions, re-
veals a substantial beneﬁt of EVAR over OS in stable and
in unstable rAAA patients. Admittedly, institutions
enrolled in NSQIP are selected from the larger cohort
of hospitals that treat rAAA.
This study, based on the NSQIP database, has many
strengths not found in other studies, including a large sam-
ple size that enables smaller CIs in the assessment of risk
factors. The current study also presents a representative es-
timate of outcomes in a broad population derived from
community and academic hospitals from across the nation.
Moreover, the data from NSQIP are detailed and indepen-
dently validated and audited.
Our study also has limitations. This is a retrospective
analysis of prospectively recorded data. Variables analyzed
were limited to those recorded by NSQIP. Despite the
data set being fairly comprehensive, with >50 preopera-
tive variables, information regarding anatomy, including
vessel diameter, aneurysm size, length and diameter of
the aortic neck, calciﬁcation, aortic thrombus, tortuosity,
and presence of a suitable iliac anchoring segment was not
available.
Another limitation is that the patients undergoing OS
and EVAR were not anatomically matched. Patients un-
dergoing EVAR may have been selected for favorable
anatomy, whereas those selected for OS may have hadmore complex anatomy. Of course, if the EVAR patients
with more favorable anatomy had been treated with OS,
the outcomes of OS might have been improved. Unfortu-
nately in NSQIP, anatomic details are not available. Simi-
larly, we also do not know how many patients who
underwent OS might have been candidates for EVAR,
which was not performed due to the lack of an specialist
trained in EVAR.
The duration and location of proximal control with
clamp or balloon is not speciﬁed. The number of pa-
tients who were evaluated with a computed tomography
scan before the operation is not known. Hospital volume
and academic vs community status were not available.
Long-term morbidity and mortality, which are impor-
tant indicators of treatment success, are not available.
The reasons for return to the operating room are also
not known.
Importantly, patients were not randomized; thus, there
is no surety that patient cohorts for OS and EVAR are
identical. However, the data in Table II show that most
of preoperative variables were statistically identical when
the OS and EVAR groups were compared for both stable
and unstable patients. There were some differences; how-
ever, most often these favored EVAR patients being the
more ill of the two cohorts.
Another important limitation is that NSQIP does
not have a designation for an unstable preoperative
state. Thus, to conduct this analysis, it was necessary
for us to create a surrogate for instability. We deﬁned
instability as urgently treated patients who (1) experi-
enced preoperative shock, (2) received >4 units of pre-
operative transfusion, (3) required preoperative
intubation, or (4) had preoperative coma or impaired
sensorium. These deﬁnitions are by no means absolute;
however, we are conﬁdent that these designations have
created a cohort of patients with rAAA who are overall
quite ill. This is the patient cohort that has not been
fully evaluated in previous studies of rAAA comparing
EVAR vs OS.
CONCLUSIONS
In NSQIP participating hospitals across the coun-
try, approximately one-third of patients with rAAA
are treated with EVAR. Unstable patients have less
favorable outcomes than patients that are stable. Our
data show rather deﬁnitively that EVAR reduced mor-
tality and morbidity when used to treat patient with
rAAA, regardless of the patient’s stability. Our ﬁndings
suggest that in centers experienced with EVAR, this
may be the preferred approach for all patients present-
ing with ruptured AAA who have a favorable anatomy
for EVAR.
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